<p>根据 AlphaQuest LLC 在最近向证券交易委员会提交的 13F 表格，该公司在第一季度将其在强生（NYSE:JNJ - 免费报告）的持股增加了 26.8%。在该季度购买了额外的 2,818 股后，该机构投资者持有该公司 13,338 股股票。根据其最近的 SEC 文件，AlphaQuest LLC 在强生的持股价值为 2,212,000 美元。</p>
<ul>
<li>JNJ 股票上涨表明对新增长路径的信心</li>
</ul>
<p>其他机构投资者和对冲基金也买卖了该公司的股票。Highline Wealth Partners LLC 在第一季度将其在强生的股份增加了 51.8%。Highline Wealth Partners LLC 现在拥有 252 股该公司的股票，价值 42,000 美元，此前在上个季度购买了 86 股。Stone House Investment Management LLC 在第一季度获得了强生的新头寸，价值 47,000 美元。von Borstel &amp; Associates Inc.在第一季度获得了强生的新头寸，价值 49,000 美元。Capital A Wealth Management LLC 在第四季度获得了强生的新头寸，价值 50,000 美元。最后，Harvest Fund Management Co. Ltd 在第一季度获得了强生的新头寸，价值 52,000 美元。机构投资者持有该公司 69.55% 的股票。</p>
<p>获取 <strong>强生</strong> 的提醒：</p>
<h2>华尔街分析师预测增长</h2>
<p>一些股票分析师最近对该股票发表了看法。摩根士丹利将强生股票的目标价格从 171.00 美元上调至 176.00 美元，并在 7 月 17 日的报告中给予该股票 “持平” 评级。Benchmark 在 4 月 24 日的报告中将强生股票升级为 “强力买入” 评级。Piper Sandler 在 7 月 17 日的报告中重申了对强生股票的 “增持” 评级。花旗将强生股票的目标价格从 185.00 美元上调至 200.00 美元，并在周四给予该公司 “买入” 评级。最后，巴克莱在 7 月 17 日的研究报告中将强生股票的目标价格从 165.00 美元上调至 176.00 美元，并给予该公司 “持平” 评级。两位投资分析师对该股票给予了 “强力买入” 评级，九位给予了 “买入” 评级，九位对该公司给予了 “持有” 评级。根据 MarketBeat 的数据，该公司的共识评级为 “适度买入”，平均目标价格为 176.29 美元。</p>
<ul>
<li>3 只强劲盈利的高分红股票</li>
</ul>
<p><strong>查看我们关于 JNJ 的最新报告</strong></p>
<h2>强生股票上涨 0.0%</h2>
<p>强生股票在周五开盘价为 178.8990 美元。强生的 52 周低点为 140.68 美元，52 周高点为 180.61 美元。该公司的 50 日简单移动平均线为 163.04 美元，200 日简单移动平均线为 159.05 美元。该公司的债务与股本比率为 0.50，速动比率为 0.76，流动比率为 1.01。该公司的市值为 4308.5 亿美元，市盈率为 19.13，市盈增长比率为 2.28，贝塔值为 0.41。</p>
<ul>
<li>担心反弹消退？考虑这 3 只高分红股票</li>
</ul>
<p>强生（NYSE:JNJ - 获取免费报告）最近在 7 月 16 日发布了季度财报。该公司报告每股收益为 2.77 美元，超出市场共识预期的 2.68 美元，超出 0.09 美元。该季度的营业收入为 237.4 亿美元，而分析师预期为 228.5 亿美元。强生的净利润率为 25.00%，股本回报率为 32.49%。强生的收入同比增长 5.8%。在去年同期，该公司每股收益为 2.82 美元。强生已将其 2025 财年的指导目标设定为 10.800-10.900 每股收益。作为一个整体，卖方分析师预计强生在当前年度的每股收益为 10.58 美元。</p>
<h2>强生股息公告</h2>
<p>该公司最近还宣布了一项季度股息，将于 9 月 9 日（星期二）支付。8 月 26 日（星期二）的股东将获得 1.30 美元的股息。该股息的除息日期为 8 月 26 日（星期二）。这相当于每年 5.20 美元的股息，股息收益率为 2.9%。强生的股息支付比率为 55.61%。</p>
<h2>强生公司简介</h2>
<p>（免费报告）</p>
<p>强生是一家控股公司，专注于医疗保健领域的产品研究、开发、制造和销售。它通过创新药物和医疗技术两个部门运营。创新药物部门专注于免疫学、传染病、神经科学、肿瘤学、心血管和代谢以及肺动脉高压。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票比强生更好</li>
<li>如何有效使用 MarketBeat 评级筛选器</li>
<li>小型股，大潜力：您应该了解的 3 家科技颠覆者</li>
<li>股票中的缺口上涨意味着什么？如何利用缺口</li>
<li>在盈利未达预期后，沃尔玛仍然是顶级消费品股票</li>
<li>最佳能源股票 - 现在值得购买的能源股票</li>
</ul>
<p><strong>想看看其他对冲基金持有的 JNJ 吗？</strong> 访问 HoldingsChannel.com，获取强生（NYSE:JNJ - 免费报告）的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 1,000 美元在强生吗？</h2>
<p>在您考虑强生之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而强生并不在名单上。</p>
<p>虽然强生目前在分析师中获得了中性买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

强生

<p>AlphaQuest LLC 在第一季度将其在强生（NYSE: JNJ）的持股增加了 26.8%，额外购买了 2,818 股，总持股达到 13,338 股，价值 221 万美元。其他机构投资者也增加了他们的持股。分析师对 JNJ 的共识评级为 “适度买入”，目标价格平均为 176.29 美元。该公司报告第二季度每股收益为 2.77 美元，超出预期，并宣布季度股息为 1.30 美元，将于 9 月 9 日支付</p>

<p>AlphaQuest LLC lifted its holdings in Johnson &amp; Johnson (NYSE:JNJ - Free Report) by 26.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities &amp; Exchange Commission. The institutional investor owned 13,338 shares of the company's stock after purchasing an additional 2,818 shares during the quarter. AlphaQuest LLC's holdings in Johnson &amp; Johnson were worth $2,212,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>根据 AlphaQuest LLC 在最近向证券交易委员会提交的 13F 表格，该公司在第一季度将其在强生（NYSE:JNJ - 免费报告）的持股增加了 26.8%。在该季度购买了额外的 2,818 股后，该机构投资者持有该公司 13,338 股股票。根据其最近的 SEC 文件，AlphaQuest LLC 在强生的持股价值为 2,212,000 美元。</p>
</div><ul>
<li>JNJ Stock Surge Signals Confidence in New Growth Path</li>
</ul>
<div class="lb-trans"><ul>
<li>JNJ 股票上涨表明对新增长路径的信心</li>
</ul>
</div><p>Other institutional investors and hedge funds have also bought and sold shares of the company. Highline Wealth Partners LLC grew its stake in Johnson &amp; Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after purchasing an additional 86 shares in the last quarter. Stone House Investment Management LLC acquired a new position in Johnson &amp; Johnson during the first quarter worth $47,000. von Borstel &amp; Associates Inc. acquired a new position in Johnson &amp; Johnson during the first quarter worth $49,000. Capital A Wealth Management LLC acquired a new position in Johnson &amp; Johnson during the fourth quarter worth $50,000. Finally, Harvest Fund Management Co. Ltd acquired a new position in Johnson &amp; Johnson during the first quarter worth $52,000. Institutional investors own 69.55% of the company's stock.</p>
<div class="lb-trans"><p>其他机构投资者和对冲基金也买卖了该公司的股票。Highline Wealth Partners LLC 在第一季度将其在强生的股份增加了 51.8%。Highline Wealth Partners LLC 现在拥有 252 股该公司的股票，价值 42,000 美元，此前在上个季度购买了 86 股。Stone House Investment Management LLC 在第一季度获得了强生的新头寸，价值 47,000 美元。von Borstel &amp; Associates Inc.在第一季度获得了强生的新头寸，价值 49,000 美元。Capital A Wealth Management LLC 在第四季度获得了强生的新头寸，价值 50,000 美元。最后，Harvest Fund Management Co. Ltd 在第一季度获得了强生的新头寸，价值 52,000 美元。机构投资者持有该公司 69.55% 的股票。</p>
</div><p>Get <strong>Johnson &amp; Johnson</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>强生</strong> 的提醒：</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>A number of equities analysts recently weighed in on the stock. Morgan Stanley boosted their target price on shares of Johnson &amp; Johnson from $171.00 to $176.00 and gave the stock an &#34;equal weight&#34; rating in a report on Thursday, July 17th. Benchmark upgraded shares of Johnson &amp; Johnson to a &#34;strong-buy&#34; rating in a report on Thursday, April 24th. Piper Sandler reiterated an &#34;overweight&#34; rating on shares of Johnson &amp; Johnson in a report on Thursday, July 17th. Citigroup upped their price objective on shares of Johnson &amp; Johnson from $185.00 to $200.00 and gave the company a &#34;buy&#34; rating in a report on Thursday. Finally, Barclays upped their price target on shares of Johnson &amp; Johnson from $165.00 to $176.00 and gave the company an &#34;equal weight&#34; rating in a research note on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $176.29.</p>
<div class="lb-trans"><p>一些股票分析师最近对该股票发表了看法。摩根士丹利将强生股票的目标价格从 171.00 美元上调至 176.00 美元，并在 7 月 17 日的报告中给予该股票 “持平” 评级。Benchmark 在 4 月 24 日的报告中将强生股票升级为 “强力买入” 评级。Piper Sandler 在 7 月 17 日的报告中重申了对强生股票的 “增持” 评级。花旗将强生股票的目标价格从 185.00 美元上调至 200.00 美元，并在周四给予该公司 “买入” 评级。最后，巴克莱在 7 月 17 日的研究报告中将强生股票的目标价格从 165.00 美元上调至 176.00 美元，并给予该公司 “持平” 评级。两位投资分析师对该股票给予了 “强力买入” 评级，九位给予了 “买入” 评级，九位对该公司给予了 “持有” 评级。根据 MarketBeat 的数据，该公司的共识评级为 “适度买入”，平均目标价格为 176.29 美元。</p>
</div><ul>
<li>3 Big Dividend Plays With Strong Earnings to Back Them</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只强劲盈利的高分红股票</li>
</ul>
</div><p><strong>Check Out Our Latest Report on JNJ</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 JNJ 的最新报告</strong></p>
</div><h2>Johnson &amp; Johnson Trading Up 0.0%</h2>
<div class="lb-trans"><h2>强生股票上涨 0.0%</h2>
</div><p>JNJ stock opened at $178.8990 on Friday. Johnson &amp; Johnson has a 52 week low of $140.68 and a 52 week high of $180.61. The company's 50-day simple moving average is $163.04 and its 200 day simple moving average is $159.05. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The company has a market capitalization of $430.85 billion, a PE ratio of 19.13, a price-to-earnings-growth ratio of 2.28 and a beta of 0.41.</p>
<div class="lb-trans"><p>强生股票在周五开盘价为 178.8990 美元。强生的 52 周低点为 140.68 美元，52 周高点为 180.61 美元。该公司的 50 日简单移动平均线为 163.04 美元，200 日简单移动平均线为 159.05 美元。该公司的债务与股本比率为 0.50，速动比率为 0.76，流动比率为 1.01。该公司的市值为 4308.5 亿美元，市盈率为 19.13，市盈增长比率为 2.28，贝塔值为 0.41。</p>
</div><ul>
<li>Worried About a Fading Rally? Consider These 3 Dividend Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>担心反弹消退？考虑这 3 只高分红股票</li>
</ul>
</div><p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.09. The business had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. Johnson &amp; Johnson had a net margin of 25.00% and a return on equity of 32.49%. Johnson &amp; Johnson's revenue was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.82 earnings per share. Johnson &amp; Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, sell-side analysts anticipate that Johnson &amp; Johnson will post 10.58 earnings per share for the current year.</p>
<div class="lb-trans"><p>强生（NYSE:JNJ - 获取免费报告）最近在 7 月 16 日发布了季度财报。该公司报告每股收益为 2.77 美元，超出市场共识预期的 2.68 美元，超出 0.09 美元。该季度的营业收入为 237.4 亿美元，而分析师预期为 228.5 亿美元。强生的净利润率为 25.00%，股本回报率为 32.49%。强生的收入同比增长 5.8%。在去年同期，该公司每股收益为 2.82 美元。强生已将其 2025 财年的指导目标设定为 10.800-10.900 每股收益。作为一个整体，卖方分析师预计强生在当前年度的每股收益为 10.58 美元。</p>
</div><h2>Johnson &amp; Johnson Dividend Announcement</h2>
<div class="lb-trans"><h2>强生股息公告</h2>
</div><p>The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.9%. Johnson &amp; Johnson's dividend payout ratio is 55.61%.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项季度股息，将于 9 月 9 日（星期二）支付。8 月 26 日（星期二）的股东将获得 1.30 美元的股息。该股息的除息日期为 8 月 26 日（星期二）。这相当于每年 5.20 美元的股息，股息收益率为 2.9%。强生的股息支付比率为 55.61%。</p>
</div><h2>Johnson &amp; Johnson Company Profile</h2>
<div class="lb-trans"><h2>强生公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Johnson &amp; Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.</p>
<div class="lb-trans"><p>强生是一家控股公司，专注于医疗保健领域的产品研究、开发、制造和销售。它通过创新药物和医疗技术两个部门运营。创新药物部门专注于免疫学、传染病、神经科学、肿瘤学、心血管和代谢以及肺动脉高压。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Johnson &amp; Johnson</li>
<li>How to Effectively Use the MarketBeat Ratings Screener</li>
<li>Small Cap, Big Potential: 3 Tech Disruptors You Should Know About</li>
<li>What Does a Gap Up Mean in Stocks? How to Play the Gap</li>
<li>After Earnings Miss, Walmart Is Still a Top Consumer Staples Play</li>
<li>Best Energy Stocks - Energy Stocks to Buy Now</li>
<li>How Cisco Is Building a New Growth Story for Investors</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比强生更好</li>
<li>如何有效使用 MarketBeat 评级筛选器</li>
<li>小型股，大潜力：您应该了解的 3 家科技颠覆者</li>
<li>股票中的缺口上涨意味着什么？如何利用缺口</li>
<li>在盈利未达预期后，沃尔玛仍然是顶级消费品股票</li>
<li>最佳能源股票 - 现在值得购买的能源股票</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding JNJ?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson &amp; Johnson (NYSE:JNJ - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有的 JNJ 吗？</strong> 访问 HoldingsChannel.com，获取强生（NYSE:JNJ - 免费报告）的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=JNJ"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Johnson &amp; Johnson Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元在强生吗？</h2>
</div><p>Before you consider Johnson &amp; Johnson, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑强生之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而强生并不在名单上。</p>
</div><p>While Johnson &amp; Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然强生目前在分析师中获得了中性买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

AlphaQuest LLC 收购了 2,818 股强生公司股票 $JNJ